Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance

Neuropsychopharmacology

Volumn 31, Issue 5, 2006, Pages 941-955

  Segal, David S ^a   Kuczenski, Ronald ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal model; Dopamine; Locomotion; Methamphetamine; Microdialysis; Pharmacokinetics; Stereotypy

Indexed keywords

DOPAMINE; METHAMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABUSE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIZATION; DRUG TOLERANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION;

AMPHETAMINE-RELATED DISORDERS; ANESTHESIA, INTRAVENOUS; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EXTRACELLULAR FLUID; HUMANS; MALE; METHAMPHETAMINE; MICRODIALYSIS; MOTOR ACTIVITY; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION;

EID: 33646142075     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300865     Document Type: Article

References (75)

1. Anggard E, Jonsson LE, Hogmark AL, Gunne LM (1973). Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 14: 870-880.
2. Angrist B (1987). Clinical effects of central nervous system stimulants: a selective update. In: Engel J, Oreland L (eds). Brain Reward Systems and Abuse. Raven Press: New York. pp 109-127.
3. Angrist B (1994). Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS (eds). Amphetamine and its Analogues. Academic Press: San Diego. pp 387-414.
4. Angrist B, Corwin J, Bartlik B, Cooper T (1987). Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry 22: 1357-1368.
5. Arai I, Shimazoe T, Shibata S, Inoue H, Yoshimatsu A, Watanabe S (1996). Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats. Brain Res 729: 277-280.
6. Ben Shahar O, Ahmed SH, Koob GF, Ettenberg A (2004). The transition from controlled to compulsive drug use is associated with a loss of sensitization. Brain Res 995: 46-54.
7. Brown WA, Corriveau DP, Ebert MH (1978). Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology 58: 189-195.
8. Cadet JL, Jayanthi S, Deng XL (2003). Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17: 1775-1788.
9. Cho AK, Melega WP, Kuczenski R, Segal DS (2001). Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39: 161-166.
10. Cho AK, Melega WP, Kuczenski R, Segal DS, Schmitz DA (1999). Caudate-putamen dopamine and stereotypy response profiles after intravenous and subcutaneous amphetamine. Synapse 31: 125-133.
11. Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155: 397-404.
12. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM et al (1993). Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21: 717-723.
13. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE et al (1992). Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 20: 856-862.
14. Costall B, Naylor RJ (1977). Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat. In: Ellinwood EH Jr, Kilbey MJ (eds). Cocaine and Other Stimulants. Plenum Press: New York. pp 47-76.
15. Cryan JF, Hoyer D, Markou A (2003). Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54: 49-58.
16. Davidson C, Gow AJ, Lee TH, Ellinwood Jr EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36: 1-22.
17. 2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons' in the cerebral cortex. J Neurochem 88: 1003-1009.
18. Dickson PR, Lang CG, Hinton SC, Kelley AE (1994). Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study. Neuroscience 61: 81-91.
19. Ellinwood Jr EH, Lee TH (1983). Effect of continuous systemic infusion of D-amphetamine on the sensitivity of nigral dopamine cells to apomorphine inhibition of firing rates. Brain Res 273: 379-383.
20. Ellison G, Eison MS, Huberman HS, Daniel F (1978). Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 201: 276-278.
21. 1H MRS study. Neurology 54: 1344-1349.
22. Foltin RW, Haney M (2004). Intranasal cocaine in humans: acute tolerance, cardiovascular and subjective effects. Pharmacol Biochem Behav 78: 93-101.
23. Ghitza UE, Fabbricatore AT, Prokopenko V, Pawlak AP, West MO (2003). Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine. J Neurosci 23: 7239-7245.
24. Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M et al (2003). A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42: 1234-1241.
25. Griffith JD, Gunne LM (1977). Effects of amphetamines in humans. In: Martin JR (ed). Drug Addiction II. Springer-Verlag: New York. pp 247-275.
26. Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR (1996). Mechanisms for tolerance to methamphetamine effects. Neuropharmacology 35: 751-757.
27. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT (2003a). The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 74: 475-486.
28. Harris DS, Reus VI, Wolkowitz OM, Mendelson JE, Jones RT (2003b). Altering cortisol level does not change the pleasurable effects of methamphetamine in humans. Neuropsychopharmacology 28: 1677-1684.
29. Hutchaleelaha A, Mayersohn M (1996). Influence of activated charcoal on the disposition kinetics of methamphetamine enantiomers in the rat following intravenous dosing. J Pharm Sci 85: 541-545.
30. Kalechstein AD, Newton TF, Green M (2003). Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropschiatry Clin Neurosci 15: 215-220.
31. Kitaichi K, Morishita Y, Doi Y, Ueyama J, Matsushima M, Zhao YL et al (2003). Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur J Pharmacol 464: 39-48.
32. Kuczenski R, Melega WP, Cho AK, Segal DS (1997a). Extracellular dopamine and amphetamine following systemic amphetamine administration: comparison to the behavioral response. J Pharmacol Exp Ther 282: 591-596.
33. Kuczenski R, Segal DS (1989). Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9: 2051-2065.
34. Kuczenski R, Segal DS (1992). Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther 262: 1085-1094.
35. Kuczenski R, Segal DS, Aizenstein ML (1991). Amphetamine, fencamfamine, and cocaine: relationships between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11: 2703-2712.
36. Kuczenski R, Segal DS, Todd PK (1997b). Behavioral sensitization and extracellular dopamine responses to amphetamine after various treatments. Psychopharmacology 134: 221-229.
37. 11C]WIN-35 428. J Neurosci 18: 8417-8422.
38. McTavish SFB, McPherson MH, Sharp T, Cowen PF (1999). Attenuation of some subjective effects of amphetamine following tyrosine depletion. J Psychopharmacol 13: 144-147.
39. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995). Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274: 90-96.
40. Mendelson J, Jones RT, Upton R, Jacob III P (1995). Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 57: 559-568.
41. O'Connor KA, Porrino LJ, Davies HML, Childers SR (2005). Time-dependent changes in receptor/G-protein coupling in rat brain following chronic monoamine transporter blockade. J Pharmacol Exp Ther 313: 510-517.
42. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ et al (2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 23: 113-126.
43. Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L et al (2005). Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 30: 821-832.
44. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Hill JM et al (1991). Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 14: 352-358.
45. Rivière GJ, Byrnes KA, Gentry WB, Owens SM (1999). Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291: 1220-1226.
46. Rivière GJ, Gentry WB, Owens SM (2000). Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292: 1042-1047.
47. Roberts DCS, Zis AP, Fibiger HC (1975). Ascending catecholamine pathways and amphetamine induced locomotion: importance of dopamine and apparent noninvolvement of norepinephrine. Brain Res 93: 441-454.
48. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11: 157-198.
49. Robinson TE, Whishaw IQ (1988). Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209-224.
50. Roffler-Tarlov S, Sharman D, Tegerdine P (1971). 3,4-Dihydroxyphenyl-acetic acid in the mouse striatum: a reflection of intra-and extra-neuronal metabolism of dopamine? Br J Pharmacol 42: 343-351.
51. Samaha A-N, Mallet N, Ferguson SM, Gonon F, Robinson TE (2004). The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 24: 6362-6370.
52. Saunders C, Ferrer JV, Shi L, Chen JY, Merrill G, Lamb ME et al (2000). Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97: 6850-6855.
53. Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK et al (1985). Studies on the mechanism of tolerance to methamphetamine. Brain Res 343: 305-313.
54. Segal DS, Kuczenski R (1987). Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242: 917-926.
55. Segal DS, Kuczenski R (1992). In vivo microdialysis reveals a diminished amphetamine-induced dopamine response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment. Brain Res 571: 330-337.
56. Segal DS, Kuczenski R (1997a). An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17: 2551-2566.
57. Segal DS, Kuczenski R (1997b). Repeated binge exposure to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther 282: 561-573.
58. Segal DS, Kuczenski R (1999). Escalating dose/binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen/nucleus accumbens dopamine responses. Psychopharmacology 142: 182-192.
59. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005). Prolonged exposure to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology 180: 501-512.
60. Segal DS, Mandell AJ (1974). Long-term administration of D-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 2: 249-255.
61. Segal DS, Schuckit MA (1983). Animal models of stimulant-induced psychosis. In: Creese I (ed). Stimulants: Neurochemical, Behavioral and Clinical Perspectives. Raven Press: New York. pp 131-167.
62. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H et al (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214.
63. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W (2002). Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21: 61-74.
64. Strakowski SM, Sax KW (1998). Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans. Biol Psychiatry 44: 1171-1177.
65. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM (2001). Human response to repeated low-dose D-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 25: 548-554.
66. Strakowski SM, Sax KW, Setters MJ, Keck Jr PE (1996). Enhanced response to repeated D-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry 40: 872-880.
67. Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill LL, Posner K et al (2002). The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6(Suppl 1): S73-S88.
68. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF (1986). The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol Biochem Behav 25: 233-248.
69. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y et al (2004). Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24: 6028-6036.
70. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler MJ et al (2001). Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 158: 383-389.
71. Vollm BA, de Araujo IE, Cowen PJ, Rolls ET, Kringelbach ML, Smith KA et al (2004). Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 29: 1715-1722.
72. Wachtel SR, De Wit H (1999). Subjective and behavioral effects of repeated d-amphetamine in humans. Behav Pharmacol 10: 271-281.
73. Westerink BHC, Korf J (1976). Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain. Eur J Pharmacol 37: 249-255.
74. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703.
75. Zahniser NR, Sorkin A (2004). Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47: 80-91.